drugset / Trial / NCT04310527

Bioavailability of Enasidenib (CC-90007) Sprinkle Formulation Relative to the Reference Tablet Formulation and Effect of Food on the Pharmacokinetics of Sprinkle Formulation in Healthy Adults

NCT04310527

Phase 1 Completed 28 enrolled Celgene Corporation
RandomizedCrossoverOpen-labelTreatment

Summary

This is an open-label, single-center, randomized, three-period, two-sequence crossover study in healthy adult subjects to occur at one site in the United States. This study will evaluate the relative Bioavailability (BA) of an enasidenib sprinkle formulation, compared to the reference tablet formulation, when taken in the fasted state. This study will also evaluate the Pharmacokinetics (PK) of the enasidenib sprinkle formulation after a single oral dose in the fed state to assess the food effect. The study will consist of a Screening phase, a Treatment phase, and a Follow-up phone call. Approximately 28 healthy adult subjects (males or non-pregnant females) will be enrolled.

Timeline

Start
2019-10-09
Primary completion
2019-11-27
Completion
2019-12-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Enasidenib Small molecule 100 mg Oral

Indications

No indication recorded.